TrialDiabetes care2013

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.

Julio Rosenstock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.